GlaxoSmithKline and biopharmaceutical company, Innoviva, have concluded Salford Lung Study (SLS), a Phase IIIb multi-cen...
Singapore: Singapore has completed phase I clinical trial of an oral-anti-diabetic drug developed by Department of Pharm...
Singapore: New blockbuster cancer drug from South Korea's Hanmi pharmaceuticals is in troubled waters after a patient di...
Singapore: Waters Corporation recently collaborated with Bioprocessing Technology Institute (BTI), a research institute ...
Singapore: Allen David Roses, a renowned neurologist who pioneered breakthrough research in Alzhiemer's Disease, passed ...
Singapore: With a view to speed up the approval process and improve access to breakthrough drugs, the Australian federal...
Munich: Danish Drug maker Novo Nordisk recently announced that patients treated with Semaglutide, an investigational glu...
TOKYO: Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the...
Singapore: Researchers in Singapore have developed a new protein that can alter DNA in living cells with much higher pre...
Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administrat...
Singapore: Australian company Novogen, engaged in a pilot program aimed at breakthrough development of drugs to treat a ...
Singapore: Glenmark Pharmaceuticals has started the discovery and initiation of IND enabling studies of a novel clinical...
Singapore: Investigational agent, tivozanib, has demonstrated statistically significant and clinically meaningful PFS su...
Pluristem Therapeutics Inc., Israel's developer of placenta-based cell therapy products, has reached an agreement with J...
Singapore: Australia-based Bone Medical, a biopharmaceutical company focused on the development of new medicines for mus...
Singapore: The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support o...
Japanese pharmaceutical giant Chugai Pharmaceutical Co Ltd has announced that its Actemra Subcutaneous Injection (Actemr...
Prosetta Biosciences Inc. has entered into a Feasibility and First Right of Negotiation Agreement with Japan's Takeda Ph...
